Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short (12 Months) Versus Long (36 Months) Duration of Adjuvant Treatment With the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST With a High Risk of Recurrence

NCT00116935 is registered in ClinicalTrials.gov with Scandinavian Sarcoma Group as lead sponsor.

NCT NCT00116935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short (12 Months) Versus Long (36 Months) Duration of Adjuvant Treatment With the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST With a High Risk of Recurrence
Lead sponsor
Scandinavian Sarcoma Group
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2004
Completion date
December 31, 2010
Enrollment
400 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma